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Emission computed tomographic methods for the in vivo quantification of radioligand-binding sites in human brain 
have previously been limited either by a lack of correction for possible effects of altered ligand transport or by 
highly complicated physiological models that preclude display of binding data in a detailed anatomical format. We 
investigated the application of a simplified compartmental model to the kinetic analysis of in vivo ligand binding to 
central benzodiazepine receptors. The human brain distribution of ["C]flumazenil, as determined by dynamic positron 
emission tomography, combined with metabolite-corrected arterial blood samples, permitted estimations of local cere- 
bral ligand transport and of receptor binding. This approach allows calculation of transport and binding "maps" on 
a pixel-by-pixel basis, resulting in the display of binding data in a familiar tomographic format while maintaining 
much of the physiological accuracy inherent in more complex methods. The results obtained in a study of 6 normal 
volunteers revealed good interindividual precision, with coefficients of variation between 10 and 155% of mean regional 
values, suggesting the utility of this approach in future clinical studies of benzodiazepine receptor binding. 
Frey KA, Holthoff VA, Koeppe RA, Jewett DM, Kilbourn MR, Kuhl DE. Parametric in vivo imaging of 
benzodiazepine receptor distribution in human brain. Ann Neurol 1991;30:663-672 
The potential for noninvasive imaging of cerebral 
neurotransmitter receptors and drug-binding sites has 
been demonstrated repeatedly with the use of positron 
emission tomography (PET) and with the related tech- 
nique, single-photon emission computed tomography 
(SPECT). Among the potential targets for such meth- 
ods, benzodiazepine-binding sites in the human brain 
have been successfully imaged. This binding site, re- 
ferred to as the benzodiazepine "receptor" (BZR), is 
now known to reside on one of several transmembrane 
proteins, which together constitute the gamma-amino- 
butyric acid (GABA)-activated chloride ionophore 
El-31. The GABA receptor-BZR-chloride iono- 
phore complex thus accounts for biochemical [4-61 
and physiological {6-81 interactions between a variety 
of ligands that bind to different domains including 
GABA, receptor, the BZR, a barbiturate-binding site, 
and the chloride channel. Since GABA is the predomi- 
nant and most widely distributed inhibitory neuro- 
transmitter in the mammalian brain, measurements of 
BZR binding may yield important information on syn- 
aptic function across a variety of brain regions. In addi- 
tion to providing a possible marker of neuronal integ- 
rity, in vivo BZR measurements may allow distinction 
of the site(s) of drug action or allow detection of pri- 
mary alterations in the benzodiazepine-binding site in 
a variety of neurological and psychiatric disorders. 
Prior studies with PET have documented cerebral 
uptake and distribution of several radioligands with 
high affinity for the central nervous system BZR. Stud- 
ies following the administation of { "C]flunitrazepam 
[93, [LIC]suriclone {lo], and E"C]R015-1788 (fluma- 
z e d  [FMZ]) El 1- 131 demonstrated brain uptake and 
evidence of receptor-mediated retention in the brain. 
Of the available agents, we have focused our attention 
on FMZ for a variety of reasons. First, it appears to 
have a high relative proportion of "specific" (i.e., 
receptor-mediated) retention in the brain 11 1- 141. 
Second, it is an antagonist of the BZR [ l S ,  161 and is 
devoid of significant physiological or pharmacologcal 
effects in normal individuals E171. Additionally, as an 
antagonist in in vitro assays, it demonstrates no alter- 
ation in its binding on the basis of endogenous or 
added GABA or barbiturates {G, 161. Finally, the bind- 
ing of FMZ is specific for the central BZRs (the w1 
and w2 subtypes) without significant affinity for the pe- 
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ripheral BZR (the w j  subtype) r16, 181. Thus, its spe- 
cific in vivo binding should reflect local tissue central- 
type BZR availability. 
The use of ["C}FMZ for imaging of BZR in human 
brain was initially reported by Persson and colleagues 
{ 111, and has been confirmed in several subsequent 
investigations {12-14, 19, 201. In general, the ap- 
proach to interpretation of these studies has centered 
on  the observation that the amounts and regional pat- 
terns of cerebral tracer retention are substantially al- 
tered by prior administration of competing bentodiaze- 
pines or by reducing the specific activity of the  injected 
radiotracer. A formulation for analysis of ["C]FMZ 
distribution based on the assumption of pseudoequilib- 
rium between blood and brain was presented pre- 
viously r141. In our laboratory, we investigated the 
kinetics of cerebral E1'C)FMZ uptake and retention, 
and analyzed the  results o n  the basis of formal com- 
partmental modeling 1213. In the present report, we 
describe the general imaging methods employed in our 
laboratory for {"C}FMZ studies. In  addition, a novel 
analysis on the basis of a simplified compartmental 
model is presented. This approach yields graphic 
pixel-by-pixel depictions of two parameters related to 
FMZ kinetics: the blood-to-brain transport rate con- 
stant and the brain tracer distribution volume (DV) 
relative to arterial plasma. The latter parameter is 
shown to be a precise measure and is proportional to 
local BZR availability as reported in in vitro studies. 
Materials and Methods 
Synthesis of {llC}Flumazenil 
Carbon1 1-labeled FMZ (EN-methyl-"C)FMZ) was pre- 
pared by a modification [22] of the method of MaziGre and 
associates 1233. Specific activities at the time of injection 
ranged from 300 to 1,000 Ci/mmol. 
Flumazenil Metabolite Chromatography 
A procedure for rapid chromatographic separation of authen- 
tic FMZ from labeled metabolites in arterial blood was devel- 
oped by analogy to a prior method used in the analysis of 
["C]scopolamine distribution 1241. It utilizes the rapid sepa- 
ration achievable by column chromatography, combined with 
stringent solvent elution conditions and correction for recov- 
ery on the basis of a tritiated internal standard. 
In order to characterize the chromatographic behaviors of 
FMZ and its major radiolabeled metabolites, [N-methyl- 
3HfFMZ (New England Nuclear, Boston, MA) was adminis- 
tered intravenously to a 200-g male Sprague-Dawley rat. Ap- 
proximately 15 minutes after injection, the animal was killed 
and samples of arterial blood and plasma, liver, and brain 
were collected. The solid tissues were homogenized in 4 vol 
of 95% ethanol, while aliquots of plasma underwent depro- 
teinitation by addition of 1 vol of ethanol. The ethanolic 
suspensions were centrifuged to pellet the precipitates for 1 
minute in a microcentrifuge. Aliquots of the supernatants 
and of the original whole blood and plasma samples were 
assayed for radioactivity with the use of liquid scintillation 
spectroscopy both before and after drying at 60 to 70°C. 
Additional aliquots of the ethanolic supernatants were con- 
centrated under vacuum and then chromatographed on sil- 
ica thin-layer chromatography (TLC) plates (No. 5721, 
E. Merck, Darmstadt, Federal Republic of Germany) in 
each of two solvent systems: (1) hexane-benzene-dioxane- 
ammonium hydroxide, 70:50:45:0.5; and (2) dichloro- 
methane-methanol, 9: 1. Following development and drying, 
the plates were sprayed with a fluorographic enhancer (En- 
3hance, New England Nuclear, Boston, MA) and apposed to 
x-ray film for 7 to 14 days at - 70°C. The resulting autoradio- 
grams were used to locate and recover major labeled metabo- 
lites from the plates. 
Column chromatographic separation of C3H]FMZ from 
two major labeled metabolites was investigated with the use 
of Sep-Pak C,, cartridges (Waters, Milford, MA). The col- 
umns were prewashed with 0.1 ml of triethylamine followed 
by 10 ml of methanol and 10 ml of phosphate-buffered saline 
solution (PBS): sodium chloride (NaCI) 137 mM; potassium 
chloride (KC1) 3 mM; sodium phosphate (Na,HP04) 8 mM; 
potassium phosphate (KH,P04) 1.5 mM; pH 7.4. Samples 
of authentic C3H)FMZ or labeled metabolite fractions were 
added in 1-ml volumes of PBS. Columns were then washed 
with mobile phases of varying methanol-PBS content. Eluted 
fractions were collected and assayed by liquid scintillation 
spectroscopy 
PET Data Acquisition 
Six young volunteers were recruited by advertisement for 
participation in the study. They were free of significant cur- 
rent illness by history, had normal findings on general physi- 
cal and neurological examinations, were not taking prescrip- 
tion or over-the-counter medications with central nervous 
system actions, were nonsmokers, and did not consume ex- 
cessive amounts of alcohol or caffeine. informed consent was 
obtained prior to all studies, and the procedures were ap- 
proved by the local institutional review boards governing the 
use of radionuclides and human subjects in research. 
The PET imaging was performed with a CTI/Siemens 
93 1/08-12 scanner (Siemens Gammasonics, Inc, Hoffman 
Estates, IL) in the stationary acquisition mode. The tomo- 
graph has a reconstructed spatial resolution of 6- to 7-mm 
full width at half maximum (FWHM) within planes and 7- to 
8-mm FWHM in the axial direction. Data from eight rings 
are simultaneously acquired, permitting reconstruction of 15 
planes, each separated by 6.75 mm. 
Following establishment of percutaneous radial artery and 
venous access, subjects were positioned supine, with the eyes 
and ears unoccluded. The scanned field of view encompassed 
approximately 100 mm, beginning inferiorly at 1.0 cm above 
the orbitomeatal line. Five radioactive fiduciary markers, 1 
to 2 mm in diameter, each labeled with approximately 8 LCi 
of "C, were affixed to the scalp within the field of view. A 
dynamic series of PET scans was initiated following bolus 
intravenous injection of 30 to 50 mCi of {"CIFMZ, con- 
taining less than 30 kg of ligand. Scans were acquired over 
the following 90 minutes according to the following protocol: 
4 x 30 seconds; 3 x 1 minute; 2 x 2.5 minutes; 2 X 5 
minutes; and 7 x 10 minutes. 
Timed arterial blood samples were withdrawn into hepa- 
rinized syringes every 10 seconds for the first 2 minutes, 
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followed by additional discrete samples at progressively 
longer intervals throughout the remainder of the scanning 
session. Following centrifugation, plasma aliquots were as- 
sayed for total radioactivity with the use of a sodium iodide 
well-counter. Additional aliquots were processed by column 
chromatography at 1, 2, 3, 4 ,  5, 7.5,  10, 15, 20, 30, 45 ,  60, 
and 90 minutes to quantify the unmetabolized ["CIFMZ 
fraction. These latter plasma samples of 0.4 ml were added to 
tubes containing 0.6 ml of PBS, which additionally contained 
approximately 0.05 pCi of C3H)FMZ to act as an internal 
standard for recovery. Following application to the Sep-Pak 
column, samples were washed with 9 ml of PBS-methanol, 
6535. The unmetabolized fraction was then eluted from the 
column with 5 ml of methanol. The wash and FMZ fractions 
thus obtained were assayed for "C activity in the well- 
counter. Aliquots were taken for assay of 3H by liquid scintil- 
lation spectroscopy following decay of "C. The unmetabo- 
lized fraction of [ "C)FMZ in the original plasma sample was 
then calculated as described elsewhere 1241. Total arterial 
plasma {"CIFMZ was used as the input function for compart- 
mental analysis, since prior work demonstrated only slight 
plasma protein binding [25J 
The emission scans were reconstructed and realigned to a 
common spatial orientation on the basis of the scalp fiducia- 
ries. The images were corrected for attenuation by calculation 
with the use of an ellipse, and were scaled to account for the 
differing scan acquisition times and for "C decay. 
Prior receptor radioligand biodistribution experiments 
from our laboratory have been analyzed with the use of a 
compartmental model that distinguishes free, nonspecifically 
bound, and specifically bound tracer in tissue (Fig 1) [26}. 
Detailed analysis of the kinetic behavior of ["C}FMZ in hu- 
man brain indicates that the tissue tracer pools are in rapid 
exchange, allowing simplification to a single tissue compart- 
ment representing the combined tracer pools [21]. In this 
case, the mathematical description of regional brain activity 
C+ versus time t is given by: 
where 
and where C,(t) is the tracer activity in arterial plasma; @ 
denotes the operation of convolution; f represents local cere- 
bral blood flow; PS represents the capillary permeability- 
surface area product; and rate constants a, b, and K, through 
kd are as defined in the legend to Figure 1. The PET data, 
omitting the first 30 seconds to minimize effects of intravas- 
cular activity, were fit to the relationship in Equation 1 on a 
pixel-by-pixel basis with the use of the metabolite-corrected 
arterial input curve and a weighted integral lookup table ap- 
proach 127, 28). This allows calculation and display of two 
parametric maps, one reflecting ligand transport from blood 
to brain (KJ, the second depicting the local ligand DV. The 
DV is related to the model parameters and to regional recep- 
tor availability as follows: 
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Fig I .  Model describing f"C)junazenil distribution in brain 
as detemzined by PET. The inner compartments represent the 
greatest complexity o f  ligand environments considered, inchding 
ligand in arterial plasma (C,) as well as free (CF), nonspecbfi- 
cally bound (CNs), and spec;fically bound (C,) pools in  the 
brazn. Kinetic rate constants Kl and k2 describe exchange be- 
tween the arterial plasma and free tissue pools, constants k, and 
R,  relate nonspecrjk binding to  free ligand in  tissue, and con- 
stants k, and k4 describe speczfic receptor binding of ligand and 
its drssociation, respectively. The outer two compartments demon- 
strate the relationships of these lzgandpools t o  the simpli3ed 
model employed in the present study. The combined activity in 
tissue pools I S  represented by C,, and the parameters a and b de- 
scribe the transport from plasma t o  brain and net loss of tracer 
from brain t o  pkzsma, respectively. 
where 
and thus, 
where k,, and kOfi are the kinetic rate constants for ligand 
receptor binding and dissociation, R is the available receptor 
concentration, and KD is the equilibrium binding affinity con- 
stant. In the case of a ligand with relatively high affinity for 
receptor-binding sites (low KD), and when there are large 
concentrations of receptors avadable for binding, the DV is 
dominated by k,/k, and is proportional to R. 
Following calculation of parametric images of K, and DV, 
whole-brain and selected region-of-interest analyses were 
performed. Regions were identified according to the K1 im- 
ages, as these afforded good brain structural delineation, even 
in regions with relatively low BZR binding. The regions were 
then mapped onto the corresponding tissue activity and para- 
metric DV images. Average brain parameter estimates were 
accomplished by calculation of the weighted mean of all 15 
whole-slice regions. Whole-brain uptake was then estimated 
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Fig 2. Thin-layer chromatography of labeled flumazenil (FMZ) 
and metabolites. An autordiograph is shown of the chromato- 
graphic separation of activity extracted from the liver, plasma, 
and brain following in  vivo injection, using the methylene 
chloride-methanol solvent system described in  the text. In a&- 
tion t o  FMZ, two groups Of labeled metabolites are identified in  
the liver and plasma, designated bands I and I I .  Note that 
there is no detectable nonvolatile activity in  tbe brain other than 
that associated with FMZ. The quantitatively mittor bands 
present in  the {'H}FMZ standard lane rejlect impurities ac- 
counting for less than 3 % of the total activity. 
by assumption of a brain volume of 1,237 ml for normal 
young adults [29]. 
Results 
Metabolic Fate of {'H)FLumazenil in the Rat 
Following systemic injection, I3H]FMZ is rapidly me- 
tabolized. Comparison of total and nonvolatile activi- 
ties revealed the presence of significant amounts of 
volatile metabolites, which account for over 955% of 
the activity in plasma and for 15 to 20% of the activity 
in brain and liver at 15 minutes after injection. Chro- 
matographic analysis of nonvolatile activity (Fig 2) re- 
vealed the presence of two classes of labeled polar me- 
tabolites, one remaining at the origin (band I) and a 
second (band 11) migrating with an & approximately 
two thirds that of authentic FMZ. Unchanged FMZ 
accounted for over 995% of nonvolatile brain activity, 
but only 32% and 14% of that recovered from plasma 
and liver, respectively. In plasma, 63% of the nonvola- 
tile activity was in band I and 6% was attributable to 
band 11. 
Rapid Column Chromatography of Flumazenil 
in Plasma 
Samples of both 'H-labeled metabolites and of 
C3H}FMZ were applied to Sep-Pak columns and eluted 
with mobiie phases containing PBS and between 0 and 
45% methanol. The best differential retention of FMZ 
versus the metabolites was achieved with use of 35% 
methanol. In this case, washing of the column with 8 
ml removed over 98% of the band I and 91% of the 
band I1 metabolite activities, while retaining 505% of 
the FMZ applied (Fig 3). In the subsequent processing 
of arterial samples from human studies, a 9-ml wash 
volume was adopted to further ensure high purity of 
the FMZ fraction. 
10 2.5 5.0 0 2 4 6 a 
(----35% Methanol:65% Saline----)(lOO% Methanol) 
Volume of Mobile Phase, ml 
F i g  3 .  Column chronzatography of labeledjumazenil (FMZ) 
and metabolites prepared from rat liver. Representative elutions 
of[jH}FMZ (closed circles) and two groups of labeled polar 
metabolites, designated bands I (open triangles) and 11 (open 
squares), from Sep-Pak C,, colamns initially with f;ve 2-ml 
volumes qf 35 % methanol-65 PBS, and then followed by 
two 2.5-ml volumes of 100% methanol, are shown. 
1 I 
lo3 4 I I I I 
0 15 30 45 60 75 90 
Time Post-Injection, min 
Fig 4. Time course of activity in arterial plasma following a bo- 
lus intravenous injection of {"C)flumazenil in  a representative 
n o w 1  human volunteer (Subject 2, Table 1) .  Both total (open 
circles) and metabolite-corrected flumazenil (closed circles) ac- 
tivities are correctedfor physical decay of " C .  Note the rapid 
appearance and increase with time in activity associated with 
labeled metabolites, as indicated by the diflerence between the 
cuwes. 
In arterial plasma samples collected following injec- 
tion in humans, authentic {"C}FMZ cleared rapidly 
from the circulation (Fig 4). The presence of labeled 
metabolites was detectable within 2 to 3 minutes, and 
increased with time to account for approximately 7 5 5% 
of the activity by 90 minutes after injection. 
Uptake and Distribution of {"C}Flumazenil in 
Human Brain 
FMZ entered the brain readily, reaching peak levels in 
whole brain between 5 and 15 mintues after injection. 
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Table 1 .  Whole-Brain Uptake of {"C)Flumazenil 
Flumazenil Dose 
Average Brain 
Activity Mass % Brain Concentrationb 
Subject Age (yr)/Sex (rnCi) (I-Lg) Uptake" (nM) 
1 19lM 33 29 5.9 5.1 
2 l9lM 42 12 7.1 2.5 
3 31lM 48 14 4.5 1.9 
4 191F 41 29 12.0 10.4 
5 19lF 46 19 8.4 4.8 
6 251F 50 19 7.9 4.5 
'Calculated on the basis of the injected activity and the weighted average of ["C]flumazenil activity within all scanned slices between 5 and 7.5 
minutes after injection, assuming a whole-brain volume of 1,237 ml. 
bCalculated from the weighted average of [''Clflumazenil activity within all scanned slices between 5 and 7.5 minutes after iniection and the 
specific activity of the injected tracer. 
The whole-brain uptake of ["CJFMZ between 5 and 
7.5 minutes after injection was 9.3 2 3.5% (mean t 
standard deviation) of the ,injected dose, resulting in 
an average brain concentration of 6 * 4 nM (Table 1). 
Analysis of regional time-activity curves indicated rapid 
ligand uptake across a wide variety of gray matter struc- 
tures with differential retention according to the antici- 
pated regional BZR density (Fig 5). Thus, activity 
cleared most slowly from the cerebral cortex; at an 
intermediate rate from the basal ganglia, thalamus, and 
cerebellar cortex; and most rapidly from the pons. 
Simplified Compartmental Analysis of Regional 
{"C}Flzlmazenil Distribution 
Parametric images of FMZ transport (Fig 6) qualita- 
tively resembled maps of cerebral blood flow. They 
revealed a relatively homogeneous pattern across ma- 
jor gray matter structures, with considerably lower val- 
ues observed in white matter, resulting in excellent 
brain structural definition in the images. By compari- 
son, the DV images revealed large differences across 
gray matter structures, correlating with known varia- 
tions in in vitro BZR concentration [so, 31). Thus, 
DV was highest in the cerebral cortex, with progres- 
sively lower values observed in the thalamus, cerebellar 
cortex, caudate, and pons. Images of regional ligand 
concentration between 15 and 20 minutes after injec- 
tion, as the distribution increasingly reflects specific 
binding and may approach a pseudoequilibrium be- 
tween free and bound ligand, were qualitatively similar 
to the parametric images of DV. 
Region-of-interest analysis (Table 2) of the two para- 
metric images and of the delayed 15- to 20-minute 
ligand concentration confirmed the previous observa- 
tions from visual inspection of the images. Regional 
gray matter K, values ranged from 0.23 to 0.35 ml 
plasma/mI brain/min with coefficients of variation 
(COV) between 10 and 15% of the mean values. Aver- 
age regional ligand DVs ranged from 1.0 to 5.4 ml 
0 15 30 45 60 75 90 
Time Post-In]ection, min 
Fig 5 .  Time course of regional brain activity following a bolus 
intravenous injection of f'C}$umuzenil in a representative nor- 
mal human volunteer (Subject 2, Table 1). All measurements 
are corrected for physical decuy of "C. Note the similarly rapid 
extraction followed by differential retention in frontal cortex 
(open diamonds), thalamus (closed triangles), putamen 
(open squares), cerebellum (open circles), and the pons 
(closed inverted triangles). 
plasmaim1 brain in the pons and the occipital cortex, 
respectively, with COVs between 10 and 14%. Fur- 
ther improvement in precision was achieved in most 
regions by representing the parameters as regional ra- 
tios to the whole-brain average for each study. In this 
case, COVs for K, and for DV ranged between 2 and 
11%, with the exception of the pons, where no signifi- 
cant improvement was noted. 
Discussion 
The present study confirmed and extended prior find- 
ings indicating the utility of radiolabeled FMZ in the 
in vivo measurement of central BZR availability. In 
agreement with studies on the metabolism of pharma- 
cological doses of FMZ [25, 321 and of tracer doses of 
["CIFMZ [33] ,  we found evidence in both the rat and 
Frey et al: Flumazenil-binding Maps 667 
Fig  6. Parametric images of {''C)flumazenil transport and dis- 
tribution volume, and delayed tissue activity in a representative 
normal volunteer. Images represent five matching transaxial 
levels selected from sets of 15 simultaneously scanned planes. 
Note similar ligand transport across gray matter structures, 
compared with substantiahji louxr values in the white matter 
(top row). The ligand distribution volume images (middle 
row) demonstrate distinction between areas of  highest benzodiaz- 
epine receptor numbers within the cerebral cortex and regions of 
fmer benzodiazepine receptors, including the thalamus (level 2), 
basal ganglia (levels 2 and 3), cerebellar cortex (level 5) ,  and the 
pons (level 5). Images of {"C}jumazenil activity between 15 
and 20 minutes afer injection (bottom row) resemble the dis- 
tribution volume maps; however, they demonstrate relatively 
greater activity in the thalamus and cerebellum. All images are 
pseudocolor maps depicting the displayed variable from highest 
(white) t o  lowest (violet) values according t o  the color scale at the 
h e r  right. 
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Table 2.  Regionaf Brain Flnmazenil Concentrution and Kinetic Pummeter EJ timate.ra 
Brain 
Region K? DV' Activityd K, DV Activity 
Occipital cortex 0.30 -C 0.04 5.4 * 0.7 0.081 * 0.029 1.17 % 0.10 1.32 -C 0.07 1.30 ;t 0.07 
Frontal cortex 0.29 ? 0.03 4.8 ? 0.5 0.073 * 0.024 1.13 2 0.02 1.17 2 0.04 1.18 k 0.04 
Caudate 0.31 2 0.04 2.3 * 0.2 0.037 k 0.013 1.20 _t 0.07 0.56 f 0.05 0.61 ? 0.04 
Putamen 0.32 rt 0.05 3.0 * 0.4 0.049 f 0.015 1.26 I 0.07 0.75 * 0.02 0.79 2 0.02 
Thalamus 0.35 * 0.05 2.9 t 0.4 0.050 0.018 1.37 2 0.10 0.70 k 0.06 0.81 2 0.04 
Cerebellum 0.28 t 0.03 2.8 2 0.4 0.048 2 0.017 1.10 ? 0.06 0.70 & 0.08 0.78 ? 0.08 
Pons 0.23 * 0.04 1.0 0.1 0.014 ? 0.006 0.90 & 0.15 0.24 k 0.03 0.23 k 0.05 
Whole braine 0.26 r+ 0.03 4.1 ? 0.5 0.062 k 0.021 
Relative to Whole Brain 
"Values represent the mean 2 standard deviation of observations from 6 individuals. 
h ~ d u e s  are in ml of arterial plasmdm1 of tissueimin. 
'Values are in ml of arterial plasmaiml of tissue. 
dActivity between 15 and 20 minutes after injection expressed as pCi/ml of brainimCi of injected dose. 
eWeighted average of brain from 15 transaxial slices. 
K, = transport rate constant; DV = distribution volume. 
the human that FMZ is rapidly metabolized. However, 
chromatographic analysis of activity extracted from rat 
brain revealed that detectable levels of nonvolatile 
FMZ metabolites are excluded by the blood-brain bar- 
rier. Both of the radiolabeled FMZs employed in our 
studies were labeled in the same position (either 3H or 
"C in the N-methyl position), allowing extrapolation 
of the animal data to the human studies regarding the 
disposition of metabolites retaining the N-methyl 
group. In addition, a prior study following injection of 
the major "C-labeled FMZ metabolite, an acid FMZ 
derivative (R015-3890), revealed directly that there is 
no appreciable brain uptake in normal humans [343. 
Thus, the cerebral time-activity curves obtained in nor- 
mal human studies may be interpreted as representing 
authentic ["CIFMZ. The finding of significant relative 
amounts of volatile activity in the rat following injec- 
tion of r3H)FMZ, however, suggests the need for cau- 
tion in interpretation of total activity levels following 
its in vivo injection in experimental animals. The vola- 
tile activity in this instance is likely to reflect the pres- 
ence of'[3H)water, produced during N-demethylation, 
by 'H exchange, or both. While labeled water would 
not be produced in the human studies with ["CIFMZ, 
['lC}carbon dioxide might theoretically arise via N-de- 
methylation and subsequent oxidation of the [ "Clfor- 
maldehyde. Although the cerebral time-activity curves 
in our human experiments do not suggest the presence 
of a labeled metabolite that enters the brain and ac- 
cumulates at later times, as might be expected ,of 
{"C}carbon dioxide, it would be important to verify 
directly its absence in future clinical experiments. 
We present here a colunm chromatographic method 
for the rapid metabolite correction of arterial plasma 
samples in clinical ["C}FMZ imaging studies. The 
method is capable of handling over 15 to 20 samples 
from a single FMZ administration within the time con- 
straints imposed by the 20-minute half-life of "C. Our 
results underscore the need for chromatographic pro- 
cessing of plasma to obtain the correct tracer input 
function required in tracer kinetic analysis. Significant 
metabolism of FMZ was detectable within minutes 
following intravenous injection, and the fraction of 
plasma activity attributable to unchanged FMZ fell to 
less than 30% within 15 minutes after injection. Future 
applications of ["C)FMZ in disease states must there- 
fore be conservative in their design and interpretation. 
In cases of impaired blood-brain barrier function, some 
or all of the labeled FMZ metabolites might enter the 
brain, confounding interpretation of the PET data. 
Thus, parallel PET examinations of blood-brain barrier 
integrity may be necessary in some instances. 
The method of analysis presented here, resulting in 
parametric images of radioligand transport and of tissue 
DV, was applied previously in our laboratories to the 
imaging of muscarinic receptors [35].  An alternative 
method previously proposed for analysis of in vivo 
["CIFMZ binding {14} makes the assumption that at 
later times following injection of tracer, an equilibrium 
between free tracer and specifically bound tracer is 
achieved. In order to rigorously apply this solution, a 
scan is required at a time when the nonspecific binding 
is minimal and unchanging and when total activity in 
the brain region of interest is constant. This may theo- 
retically require scans at different times after injection 
for individual brain regions, due to local differences 
in transport and binding. An approximation of these 
conditions may be found for ligands that bind and dis- 
sociate rapidly from specific sites, by scanning late after 
injection as tracer is cleared from the brain. The simi- 
larity in regional patterns of the parametric DV and 
the 15- to 20-minute static activity images and the sub- 
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sequent quahtitdtive regional comparisons from these 
images support this assumption. However, it has been 
demonstrated that the delayed tissue activity under 
these circumstances may actually overestimate regional 
receptor availability C36, 37). This occurs when the 
relationship between specific binding and the free tis- 
sue ligand represents a secular rather than a true equi- 
librium, due to continuing decline in plasma tracer con- 
centration. Under these conditions, the overestimate 
of binding is most severe when the rate of blood clear- 
ance is greater than clearance from the brain, and 
should be most evident in regions of fewest receptors. 
Thus, the pseudoequilibrium scans in the current study 
indicate greater apparent receptor binding in the thala- 
mus, basal ganglia, and cerebellum (relative to the cere- 
bral cortex) than do the estimates from the DV maps. 
Nevertheless, the simplicity of the pseudoequilibrium 
method may ultimately allow more widespread applica- 
tion of receptor imaging, and it is readily adaptable to 
SPECT imaging of iodonated ligands, where lower 
tracer activity doses are permissible and longer image 
acquisition times are necessary. 
Our simplhed compartmental analysis appears 
promising for application to BZR measurements in 
clinical research. It is necessary, however, to validate 
further the pharmacological and physiological sensitivi- 
ties and specificities of the procedure in normal volun- 
teers and, perhaps, in patients with selected patho- 
logical conditions as well. Many of the potential 
applications of BZR imaging involve detection of re- 
ceptor losses id neurodegenerative diseases including 
Huntington's disease {30, 381, olivopontocerebellar 
atrophy [393, and Alzheimer's disease [40] or in the 
study of focal epilepsy [41, 42}. In these cases, local 
cerebral metabolism and perfusion are reduced in dis- 
crete areas of bkaiii C43-461, and it may be predicted 
that ligand transport in receptor imaging studies will 
be comparably reduced. Thus, it becomes crucial to 
isolate effects Of ligand transport from measurement of 
receptor binding in the analysis of local cerebral ligand 
concentration. The simplified two-parameter method 
presented ih the current study may prove invaluable in 
these settings, permitting simultaneous estimation of 
transport alterations in addition to receptor measure- 
ments. We have subsequently found that a shortened 
imaging period of 60 minutes following administration 
of 20 to 25 mCi of E1'C}FMZ results in parametric 
images of high quality. Test-retest experiments per- 
formed recently in our laboratory with this method 
demonstrated that augmentation of cerebral blood flow 
to the ocdpital cortex during visual stimulation results 
in increased FMZ transport, while FMZ binding esti- 
mates are unchanged {47}. 
The ihitial studies reported here reveal an unexpect- 
edly low variability in both the ligand transport and the 
DV measures. Within-individual reliability is sugested 
by the apparent favorable signal-to-noise ratios of the 
parametric images, since cerebral structure is readily 
identifiable in both parametric maps. Calculation of the 
parametric images makes use of all of the information 
recorded during the scanning session, and in the case 
of FMZ, results in images that appear favorable by 
comparison to the statistical quahty of single delayed 
images. The low between-individual coefficients of 
variation observed suggest that it should be feasible to 
detect anticipated pathological receptor changes in the 
conditions listed previously, using modest numbers of 
patients. Thus, receptor changes of 20% would be de- 
tectable at the f i  < 0.05 level with 0.8 power, using 
experimental groups of 10 subjects. Actually, the pre- 
cision of the method appears to equal or exceed those 
of the most frequently employed PET measures of me- 
tabolism or blood flow. 
A final advantage of the pixel-by-pixel fits to the 
two-parameter, two-compartment model employed 
here is in the utility of the hages  themselves. The 
pixel-by-pixel depictions of ligand transport and bind- 
ing from the present method permit visual screening 
of ligand transport and binding in the entire brain. Un- 
anticipated local changes may thus be detected without 
the need for time and labor-intensive data analyses 
needed by more complex tracer compartmental mod- 
els. The detailed kinetic descriptions of both blood and 
brain activity collected, however, will permit post hoc 
application of these more complex analyses when indi- 
cated. 
In summary, we developed a simplified compart- 
mental model and analysis of {"C}FMZ distribution in 
the human brain, which results in images of AZR bind- 
ing. Although the method requires the sampling and 
processing of arterial blood samples in addition to col- 
lection of PET data, it results in precise transport and 
binding parameter estimates. 
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